Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

Market Report, "Pulmonary Fibrosis - Pipeline Review, H2 2013", published


Print article Print article
2013-12-19 02:28:41 - Recently published research from Global Markets Direct, "Pulmonary Fibrosis - Pipeline Review, H2 2013", is now available at Fast Market Research

Global Markets Direct's, 'Pulmonary Fibrosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Pulmonary Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis. Pulmonary Fibrosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated

disease.

Full Report Details at
- www.fastmr.com/prod/755142_pulmonary_fibrosis_pipeline_review_h2 ..

Scope

* A snapshot of the global therapeutic scenario for Pulmonary Fibrosis.
* A review of the Pulmonary Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Pulmonary Fibrosis pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to Get this Report

* Identify and understand important and diverse types of therapeutics under development for Pulmonary Fibrosis.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned in this Report: Eli Lilly and Company, Lpath, Inc., Mesoblast Ltd, NicOx SA, Oncothyreon Inc, Pharmaxis Ltd., Paloma Pharmaceuticals, Inc., Digna Biotech, S.L., Aquinox Pharmaceuticals Inc., Angion Biomedica Corp., Centocor Ortho Biotech, Inc., Fibrotech Therapeutics Pty. Ltd., FCB-Pharmicell Co.,Ltd., Clarassance, Inc.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Pulmonary Fibrosis Overview
Therapeutics Development
An Overview of Pipeline Products for Pulmonary Fibrosis
Pulmonary Fibrosis Therapeutics under Development by Companies
Pulmonary Fibrosis Therapeutics under Investigation by Universities/Institutes
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Pulmonary Fibrosis Therapeutics - Products under Development by Companies
Pulmonary Fibrosis Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Pulmonary Fibrosis Therapeutics Development
Eli Lilly and Company
Lpath, Inc.
Mesoblast Ltd
NicOx SA
Oncothyreon Inc
Pharmaxis Ltd.
Paloma Pharmaceuticals, Inc.
Digna Biotech, S.L.
Aquinox Pharmaceuticals Inc.
Angion Biomedica Corp.
Centocor Ortho Biotech, Inc.
Fibrotech Therapeutics Pty. Ltd.
FCB-Pharmicell Co.,Ltd.
Clarassance, Inc.
Pulmonary Fibrosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Lpathomab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
P-17 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AZX-100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PX-866 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
STNM-04 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
P-529 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AQX-1125 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Btx-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GR-MD-02 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug For Osteoarthritis and Pulmonary Fibrosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ICG-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CG-1011 - Drug Profile
Product Description

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=755142&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.


Author:
Bill Thompson
e-mail
Web: www.fastmr.com
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com